6 stories mentioning SEER
Every FINWIRES story that references SEER, newest first.
Seer (SEER) has an average rating of Buy and mean price target of $4, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) climbed 1.6%.In corporate news, Seer (SEER) shares jumped 12% after it confirmed Monday that it has received a non-binding and unsolicited offer from its shareholder Radoff-JEC Group to acquire all its outstanding Class A shares for $2.25 per share in cash plus a contingent value right.Revolution Medicines (RVMD) shares surged 40% after it said Monday the phase 3 trial of its experimental drug daraxonrasib to treat a type of pancreatic cancer met key goals.Spyre Therapeutics (SYRE) shares jumped 23% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note. Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19. Replimune shares tumbled 63%.
Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.3%.The iShares Biotechnology ETF (IBB) climbed 1.6%.In corporate news, Seer (SEER) shares jumped 12% after it confirmed Monday that it has received a non-binding and unsolicited offer from its shareholder Radoff-JEC Group to acquire all its outstanding Class A shares for $2.25 per share in cash plus a contingent value right.
Seer (SEER) confirmed on Monday that it has received a non-binding and unsolicited offer from its shareholder Radoff-JEC Group to acquire all its outstanding Class A shares for $2.25 per share in cash plus a contingent value right.Seer said its board will engage independent financial and legal advisers to thoroughly review the proposal and determine an outcome that is in the best interests of the company and all stockholders.Radoff-JEC Group has nominated three director candidates to stand for board elections at Seer's 2026 annual meeting of stockholders, the company added.The board will present its formal recommendation about Radoff-JEC Group's director nominations in Seer's definitive proxy statement, the company said.Seer shares were more than 13% higher in Monday afternoon trading.Price: $1.92, Change: $+0.23, Percent Change: +13.31%
Health care stocks declined Monday afternoon, with the NYSE Health Care Index down 0.2% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.3%.The iShares Biotechnology ETF (IBB) added 0.8%.In corporate news, Replimune (REPL) is facing "significant risk" related to its ongoing phase 3 trial of RP1 in melanoma after the US Food and Drug Administration rejected the company's biologics license application for the product candidate, Wedbush Securities said in a note. Wedbush downgraded its rating on Replimune to neutral from outperform, with a lower price target of $2 from $19. Replimune shares tumbled 64%.Seer (SEER) shares jumped 12%. The company has received a non-binding proposal from the Radoff-JEC Group to acquire the company for $2.25 per share in cash plus a contingent value right, the latter said.Revolution Medicines (RVMD) shares surged 39% after it said Monday the phase 3 trial of its experimental drug daraxonrasib to treat a type of pancreatic cancer met key goals.Spyre Therapeutics (SYRE) shares jumped 28% after the company said its SPY001 investigational treatment for moderate-to-severely active ulcerative colitis met its primary and key secondary endpoints in a phase 2 trial.
Seer (SEER) has received a non-binding proposal from the Radoff-JEC Group to acquire the company for $2.25 per share in cash plus a contingent value right, the latter said Monday.The group, which owns about 7.6% of Seer's outstanding shares, said the offer represents a 33% premium to the company's most recent closing price and includes a contingent value right entitling shareholders to 80% of net proceeds from any sale or licensing of Seer's assets.The proposal is subject to confirmatory due diligence and assumes the company has at least $215 million in net cash and cash equivalents at closing, the Radoff-JEC group said.Seer did not immediately respond to' request for comment.Seer shares were 8.9% higher in early Monday trading.Price: $1.85, Change: $+0.16, Percent Change: +9.47%